GCM
RAPT

Graham Capital Management’s RAPT Therapeutics RAPT Stock Holding History

Graham Capital Management’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-11,835
Closed -$289K – 1297
2024
Q2 		$289K Buy
11,835
+8,921
+306% +$412K 0.01% 751
2024
Q1 		$209K Buy
+2,914
New +$405K ﹤0.01% 887

Other funds holding RAPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Graham Capital Management's RAPT Position: Q3 2024 in Review

Graham Capital Management sold out of RAPT Therapeutics (RAPT) in Q3 2024, closing a stake of 11,835 shares — an estimated $289K sold.

Graham Capital Management first reported a position in RAPT in Q1 2024 and held it in 2 quarters. The position peaked at $289K in Q2 2024. 94 funds tracked by Wall St. Rank hold RAPT as of Q3 2024.

  • Graham Capital Management reported no remaining RAPT Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Graham Capital Management sold 11,835 RAPT Therapeutics shares in Q3 2024, an estimated $289K.
  • Graham Capital Management first reported a position in RAPT Therapeutics in Q1 2024 and held it in 2 quarters.
  • Graham Capital Management's RAPT Therapeutics position peaked at $289K in Q2 2024.
  • 94 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q3 2024.

Based on Graham Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.